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Abstract
Norovirus is increasingly recognized as a major cause of acute gastroenteritis among children <5 
years of age. We searched for publications that reported detailed age distributions of pediatric 
norovirus cases, and assessed associations between age distribution and socio-demographic factors 
to identify the most critical age periods to prevent norovirus cases among young children. 
Approximately 70% of pediatric norovirus cases occurred between 6 and 23 months of age. A 
younger age distribution was found in lower income countries and inpatient settings. These 
findings suggest that a norovirus immunization schedule completed by 6 months could have the 
potential to prevent about 85% of pediatric cases, while a vaccine delivered at 12 months of age 
would only have the potential to prevent about 50% of pediatric cases. With a younger age 
distribution in lower income settings, early prevention would be even more critical.
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1. Introduction
With the substantial decline of rotavirus-associated diarrhea in countries that have 
introduced rotavirus vaccines, norovirus is increasingly recognized as a main cause of acute 
gastroenteritis (AGE) [1,2]. Norovirus vaccines are under development and have shown 
promise in safety and immunogenicity studies, as well as protection against infection and 
disease in experimental challenge studies [3,4]. Young children have the highest incidence 
of norovirus gastroenteritis [5,6], so stand to benefit from a vaccine. However all vaccine 
studies have been performed among adults. For development of a pediatric vaccine, a 
number of specific questions will arise, including the number of doses required, the 
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acceptability of an adjuvant, and the appropriate age to vaccinate. To identify the most 
critical age periods to prevent norovirus among young children, we conducted meta-analysis 
to understand the detailed age distribution of pediatric norovirus AGE cases (defined as 
children aged <5 years).
2. Methods
We used the database described in a previous systematic review [7] that included studies 
published between January 1997 and March 2014; we updated the literature search to 
include studies published between March 1, 2014, and August 31, 2014 in the Medline 
database. We searched for studies using the search term “norovirus.” Two individuals 
reviewed titles and abstracts and obtained full articles if studies were deemed relevant to our 
research. Studies that met all four of the following criteria were included: (1) recruited 
patients with AGE symptoms from a specific geographic area or group of people; (2) used 
PCR to detect norovirus in stool; (3) done continuously for ≥1 year; and (4) reported the age 
distribution among laboratory-confirmed pediatric norovirus cases.
2.1. Summary of age distributions
Data on the total number of cases and the number of cases in each age group were extracted 
from each study. After trying various categorizations (Supplementary Table/Figs. 1 and 2), 
the following four age groups were used for analyses: <6, 6–11, 12–23, and 24–59 months.
The cumulative proportion of pediatric norovirus cases by age was calculated for each study. 
We pooled this cumulative proportion of cases and calculated a weighted average. The 
following formula shows the weighted average of the cumulative proportion of pediatric 
norovirus cases by the age of 6 months:
where P(Cases 0 − 5m)i is the proportion of pediatric norovirus cases that were among the 
<6 month age group and Casesi is the total number of norovirus cases aged 0–59 months in 
study i. ∑iCasesi is the sum of all norovirus cases 0–59 months of age for all included 
studies. Similar formulae were used to calculate weighted average for <12 and <24 month 
age groups.
2.2. Association of age distribution with socio-demographic factors
Per capita gross domestic product (GDP) of each country from the year of publication was 
used as an indicator of income level [8]. Countries were additionally categorized into three 
levels of development according to World Health Organization (WHO) mortality strata [9]: 
high-mortality developing (HMD), low-mortality developing (LMD), and developed. The 
study settings were grouped into inpatient (including emergency departments), outpatient, 
community, and other. The “other” category included studies in which setting was not 
described or a mixture of settings was included but stratified data were not reported.
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We used meta-regression analyses to evaluate associations between potential predictors (i.e., 
income level and development index of each country and study setting) with the proportion 
of pediatric cases that occurred in the <12 month age group. We selected this age limit as the 
outcome because the largest variation in cumulative proportion of cases across socio-
demographic factors was observed at 12 months. Mixed-effects models were fitted using 
restricted maximum-likelihood estimation, with the number of pediatric norovirus AGE 
cases in each study as weights and “study” as a random effect. We assumed that per capita 
GDP and WHO mortality strata would indicate similar levels of development; thus we fit a 
multivariate mixed-effects model with per capita GDP and study setting. All analyses were 
performed using the package “metafor” in R [10,11].
3. Results
We identified 78 studies about pediatric norovirus from the previously developed database 
[7]. We also identified 261 publications published from March to August 2014 from the 
Medline database search. Of these, 225 articles were excluded after screening titles and 
abstracts. We assessed the eligibility of 114 full-text articles in total. Of these, 79 were 
excluded for various reasons (Supplementary Fig. 3). In total, 35 articles met the inclusion 
criteria.
There were 23 countries represented in these 35 papers. Twenty (57%) studies were 
conducted in LMD countries, representing a total of 2420 pediatric norovirus cases, eight 
(23%) were in developed countries, representing 2173 cases, and seven (20%) were in HMD 
countries, representing 607 cases. In total, there were 2347 pediatric norovirus cases in the 
inpatient setting, 1329 in outpatient, 530 in community, and 994 in other settings.
After weighting by the number of pediatric norovirus cases in each study, the percentage of 
cases in each age group was as follows: 0–5 months: 13% (95% confidence interval (CI): 7–
19%); 6–11 months: 33% (46% cumulative; 95% CI: 36–57%); 12–23 months: 36% (82% 
cumulative; 95% CI: 74–90%); and 24–59 months: 18% (100% cumulative) (Fig. 1A and 
B).
A younger age distribution of pediatric norovirus cases was observed in studies pooled from 
developing countries, with 60% (95% CI: 41–79%), 52% (95% CI: 43–61%), and 35% 
(95% CI: 12–57%) of cases among children <12 months in HMD, LMD, and developed 
countries, respectively (p = 0.09, Table 1 and Fig. 1C). A younger age distribution was 
observed in low income countries, with a decrease of 5.9% (95% CI: 1.6–10.1%) in 
cumulative cases <12 months for every 10,000 USD increase in per capita GDP (Table and 
Supplementary Fig. 4). The age distribution was younger in inpatient settings with 50% 
(95% CI: 42–59%) of cases aged <12 months, compared to 37% (95% CI: 16–57%) in 
outpatient settings and 24% (95% CI: −0.6–54%) in community settings (p = 0.01, Table 1 
and Fig. 1D).
After controlling for study setting in the multivariate model, per capita GDP remained 
significant, with the cumulative proportion of cases by 12 months reduced by 4.1% (95% 
CI: 0.8–7.5%) for every 10,000 USD increase in per capita GDP (Table 1). Although not 
statistically significant, the cumulative proportion of cases aged <12 months in inpatient 
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settings was 14% higher than that in outpatient settings in developed countries, while there 
was no difference in developing countries (Supplementary Fig. 5).
4. Discussion
Approximately 70% of pediatric norovirus-associated AGE cases occurred within the 6–23 
month age range, with less than 15% occurring before 6 months. We found a younger age 
distribution of pediatric norovirus cases in lower income settings. This might be attributable 
to a higher force of norovirus infection/basic reproduction number (R0) in low income 
settings due to poorer hygiene and sanitation and/or higher levels of contact between 
individuals [12]. These findings suggest that a norovirus immunization schedule completed 
by 6 months could have the potential to prevent about 85% of pediatric cases, while a 
vaccine delivered at 12 months of age would only have the potential to prevent about 50%. 
With a younger age distribution in lower income settings, early prevention is even more 
critical.
The proportion of cases among children aged <12 months increased from community to 
outpatient to inpatient settings. Assuming setting correlates with severity of illness, this 
suggests that the age distribution of severe norovirus cases is younger than mild cases and 
that younger cases are more likely to be hospitalized or seek medical care, consistent with 
previous studies [13,14]. This trend was apparent (though non-significant) in developed 
countries but not in developing countries. This could reflect more access to care for mild 
cases in developed countries, or a clearer triage of cases in inpatient versus outpatient 
settings. Also, there may be biases in surveillance in the individual studies that affected case 
ascertainment. For example, if older children are less likely to be hospitalized in developing 
countries, either because they do not seek care, or because they are triaged as outpatients, 
then we would observe an older distribution in developed country settings. If true, our 
observed differences could be a result of care-seeking and case detection rather than disease 
severity.
An important limitation was that few included studies were conducted in HMD countries or 
community settings, which may limit the representativeness of age distribution of these 
subgroups in the aggregated results. Also, we could not assess the age distribution by 
genogroup due to limitations in the published data, and this may be important since routes of 
GI and GII differ somewhat, and, therefore, may be associated with different age at first 
infection. Additionally, we only included studies which used PCR for norovirus detection. 
While our inclusion criteria also required cases to demonstrate AGE symptoms, the 
detection of norovirus by PCR does not necessarily imply that AGE in every case was 
caused by norovirus.
In conclusion, we found that a majority of pediatric norovirus AGE cases occurred between 
6 and 23 months. Norovirus vaccines are progressing through the development pipeline; our 
review makes clear that a pediatric formulation would need to be delivered by 6 months of 
age to prevent the majority of pediatric norovirus cases.
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Fig. 1. 
Cumulative proportion of pediatric norovirus cases (A: 35 individual studies, B: weighted 
average of cumulative proportion, C: weighted average of cumulative proportion stratified 
by country development level, D: weighted average of cumulative proportion stratified by 
study settings). Abbreviations: HMD high mortality developing countries; LMD low 
mortality developing countries.
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